- Home
- DAWN vs RVNC Comparison
DAWN vs RVNC Comparison
Compare DAWN & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- RVNC
- Stock Information
- Founded
- DAWN 2018
- RVNC 1999
- Country
- DAWN United States
- RVNC United States
- Employees
- DAWN N/A
- RVNC N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- DAWN Health Care
- RVNC Health Care
- Exchange
- DAWN Nasdaq
- RVNC Nasdaq
- Market Cap
- DAWN 1.3B
- RVNC 320.5M
- IPO Year
- DAWN 2021
- RVNC 2014
- Fundamental
- Price
- DAWN $12.79
- RVNC $3.09
- Analyst Decision
- DAWN Strong Buy
- RVNC Hold
- Analyst Count
- DAWN 7
- RVNC 9
- Target Price
- DAWN $36.17
- RVNC $8.45
- AVG Volume (30 Days)
- DAWN 937.9K
- RVNC 3.6M
- Earning Date
- DAWN 10-30-2024
- RVNC 11-07-2024
- Dividend Yield
- DAWN N/A
- RVNC N/A
- EPS Growth
- DAWN N/A
- RVNC N/A
- EPS
- DAWN N/A
- RVNC N/A
- Revenue
- DAWN $101,953,000.00
- RVNC $256,945,000.00
- Revenue This Year
- DAWN N/A
- RVNC $11.28
- Revenue Next Year
- DAWN $36.10
- RVNC $27.21
- P/E Ratio
- DAWN N/A
- RVNC N/A
- Revenue Growth
- DAWN N/A
- RVNC 25.82
- 52 Week Low
- DAWN $11.94
- RVNC $2.30
- 52 Week High
- DAWN $18.07
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- RVNC 33.47
- Support Level
- DAWN $12.26
- RVNC $3.06
- Resistance Level
- DAWN $12.81
- RVNC $3.09
- Average True Range (ATR)
- DAWN 0.52
- RVNC 0.11
- MACD
- DAWN -0.05
- RVNC 0.02
- Stochastic Oscillator
- DAWN 28.94
- RVNC 6.90
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.